Notable Labs Ltd
NASDAQ:NTBL
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IL |
|
Notable Labs Ltd
NASDAQ:NTBL
|
390k USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
392.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.8B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -11 239.1% |
| 30th Percentile | 17.6% |
| Median | 29.8% |
| 70th Percentile | 50.4% |
| Max | 208.2% |
Other Profitability Ratios
Notable Labs Ltd
Glance View
Notable Labs Ltd is a IL-based company operating in Biotechnology industry. Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Notable Labs Ltd is 37.7%, which is below its 3-year median of 60.4%.
Over the last 3 years, Notable Labs Ltd’s Gross Margin has decreased from 41% to 37.7%. During this period, it reached a low of 36.5% on Dec 31, 2023 and a high of 97.9% on Jun 30, 2023.
